Search

Your search keyword '"Fulcher, G."' showing total 442 results

Search Constraints

Start Over You searched for: Author "Fulcher, G." Remove constraint Author: "Fulcher, G."
442 results on '"Fulcher, G."'

Search Results

1. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial

9. Evidence for X(3872) in Pb-Pb Collisions and Studies of its Prompt Production at root s(NN)=5.02 TeV

10. Widdowson's Model of Communicative Competence and the Testing of Reading: An Exploratory Study.

15. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial.

16. Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program

17. Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes

18. Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program

19. A co-designed integrated kidney and diabetes model of care improves mortality, glycaemic control and self-care.

20. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program

24. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

25. P1028EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM

26. Different eGFR decline thresholds and renal effects of canagliflozin: Data from the CANVAS program

27. Health-related quality of life among patients with comorbid diabetes and kidney disease attending a codesigned integrated model of care: A longitudinal study

28. Health-related quality of life among patients with comorbid diabetes and kidney disease attending a codesigned integrated model of care: A longitudinal study.

29. SUN-128 A CO-DESIGNED INTEGRATED DIABETES AND KIDNEY DISEASE MODEL OF CARE IMPROVES DIABETES SELF-CARE AMONG PATIENTS WITH COMORBID DIABETES AND KIDNEY DISEASE.

30. SUN-129 ACTIVATION LEVELS AMONG PATIENTS WITH COMORBID DIABETES AND KIDNEY DISEASE ATTENDING A CO-DESIGNED INTEGRATED MODEL OF CARE: A LONGITUDINAL STUDY.

31. A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations.

32. SUN-128 A CO-DESIGNED INTEGRATED DIABETES AND KIDNEY DISEASE MODEL OF CARE IMPROVES DIABETES SELF-CARE AMONG PATIENTS WITH COMORBID DIABETES AND KIDNEY DISEASE

33. SUN-129 ACTIVATION LEVELS AMONG PATIENTS WITH COMORBID DIABETES AND KIDNEY DISEASE ATTENDING A CO-DESIGNED INTEGRATED MODEL OF CARE: A LONGITUDINAL STUDY

36. Updated risk factors should be used to predict development of diabetes

39. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

41. The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program

42. 1203-P: Cause of Hospitalizations in Patients with Type 2 Diabetes Mellitus (T2DM) in the CANVAS Program

46. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

47. Patient-reported barriers and outcomes associated with poor glycaemic and blood pressure control in co-morbid diabetes and chronic kidney disease

48. The impact of an integrated diabetes and kidney service on patients, primary and specialist health professionals in Australia: A qualitative study

49. The impact of an integrated diabetes and kidney service on patients, primary and specialist health professionals in Australia: A qualitative study.

50. Patient-reported barriers and outcomes associated with poor glycaemic and blood pressure control in co-morbid diabetes and chronic kidney disease.

Catalog

Books, media, physical & digital resources